Allogene on Friday released updated results from the first study of its off-the-shelf CAR-T cell therapy for an aggressive form of B-cell lymphoma. More patients are now responding, including additional patients experiencing complete remissions.
The new study results, updated from the initial disclosure two weeks ago, remain preliminary but important because they represent potential progress for the CAR-T field. If successful, the Allogene treatment, called ALLO-501, could be widely available and allow patients with advanced blood cancer to be treated on demand. Today’s bespoke CAR-Ts, by comparison, must be genetically engineered from each patient’s own cells.
Allogene is presenting the ALLO-501 data at the annual meeting of American Society of Clinical Oncology (ASCO), which starts Friday.
About the Author Reprints
